Antithrombin concentrate [48] and recombinant thrombomodulin [49] for DIC are frequently used in Japan, while eculizumab [50] has proven effective for compliment mediated TMA, such as aHUS, and rituximab [51] is effective for TTP in patients with a high titer of inhibitor for ADAMTS13. Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.